EVGN
Evogene
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Consensus Rating "Strong Buy"
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EVGN
Evogene Ltd.
A leading computational biology company that improves plant performance through seed traits and agchemicals
Biological Technology
Invalid Date
12/30/2016
NASDAQ Stock Exchange
117
12-31
Common stock
13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel
Research and develop biotechnology in the field of plant improvement.
Evogene Ltd., a leading computational biology company, aims to revolutionize the development of life science products in multiple market segments (including human health, agriculture and other industries) by leveraging cutting-edge computing technologies. The company believes that solving multiple development challenges of successful life science products by leveraging advanced computational biology platforms to identify the most promising candidates can increase the probability of success while reducing time and cost. The company believes that solving multiple development challenges of successful life science products by leveraging advanced computational biology platforms to identify the most promising candidates can increase the probability of success while reducing time and cost.
Earnings Call
Q1/2025
Estimate EPS-0.5
Actual EPS-0.38
Estimate Revenue4.42M
Actual Revenue2.44M
Evogene's 2025 Q1 Earnings Call: Contradictions in Castor Seed Sales, Financial Stability, and Production Dynamics
May 21,2025 02:33
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EVGN has released its 2025 Q1 earnings. EPS was reported at -0.38, versus the expected -0.5, beating expectations. The chart below visualizes how EVGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EVGN has released its 2025 Q1 earnings report, with revenue of 2.44M, reflecting a YoY change of -41.67%, and net profit of -2.99M, showing a YoY change of 22.26%. The Sankey diagram below clearly presents EVGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
